Dendritic cells combined with anti-GITR antibody produce antitumor effects in osteosarcoma

Kawano,Masanori; Tanaka,Kazuhiro; Itonaga,Ichiro; Iwasaki,Tatsuya; Miyazaki,Masashi; Ikeda,Shinichi; Tsumura,Hiroshi

doi:10.3892/or.2015.4161

Dendritic cells combined with anti-GITR antibody produce antitumor effects in osteosarcoma

Authors:
- Masanori Kawano
- Kazuhiro Tanaka
- Ichiro Itonaga
- Tatsuya Iwasaki
- Masashi Miyazaki
- Shinichi Ikeda
- Hiroshi Tsumura
View Affiliations

Affiliations: Department of Orthopaedic Surgery, Faculty of Medicine, Oita University, Oita 879-5593, Japan
Published online on: July 29, 2015 https://doi.org/10.3892/or.2015.4161
Pages: 1995-2001

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We attempted to enhance the antitumor effects of tumor lysate-pulsed dendritic cells by eliminating regulatory T cells. The combinatorial effects of dendritic cells and agonist anti-glucocorticoid-induced tumor necrosis factor receptor (anti-GITR) antibodies were investigated with respect to enhancement of the systemic immune response, elimination of regulatory T cells, and inhibition of tumor growth. To determine whether the combination of dendritic cells and anti‑GITR antibodies could enhance systemic immune responses and inhibit primary tumor growth in a murine osteosarcoma (LM8) model. We established the following 4 groups of C3H mice (20 mice in total): i), control IgG-treated mice; ii), tumor lysate-pulsed dendritic cell‑treated mice; iii), agonist anti-GITR antibody-treated mice; and iv), agonist anti-GITR antibody- and tumor lysate-pulsed dendritic cell‑treated mice.The mice that received the agonist anti-GITR antibodies and tumor lysate-pulsed dendritic cells displayed inhibited primary growth, prolonged life time, reduced numbers of regulatory T lymphocytes in the spleen, elevated serum interferon-γ levels, increased number of CD8+ T lymphocytes. The mice that received combined therapy had reduced level of immunosuppressive cytokines in tumor tissue and serum. Combining agonist anti-GITR antibodies with tumor lysate-pulsed dendritic cells enhanced the systemic immune response. These findings provide further support for the continued development of agonist anti-GITR antibodies as an immunotherapeutic strategy for osteosarcoma. We suggest that our proposed immunotherapy could be developed further to improve osteosarcoma treatment.

View Figures

View References

1	Ferrari S, Smeland S, Mercuri M, Bertoni F, Longhi A, Ruggieri P, Alvegard TA, Picci P, Capanna R, Bernini G, et al Italian and Scandinavian Sarcoma Groups: Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: A joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol. 23:8845–852. 2005. View Article : Google Scholar : PubMed/NCBI
2	Kager L, Zoubek A, Dominkus M, Lang S, Bodmer N, Jundt G, Klingebiel T, Jürgens H, Gadner H and Bielack S; COSS Study Group: Osteosarcoma in very young children: Experience of the Cooperative Osteosarcoma Study Group. Cancer. 116:5316–324. 2010. View Article : Google Scholar : PubMed/NCBI
3	Campbell CJ, Cohen J and Enneking WF: Editorial: New therapies for osteogenic sarcoma. J Bone Joint Surg Am. 57:143–44. 1975.PubMed/NCBI
4	Kawaguchi S, Wada T, Tsukahara T, Ida K, Torigoe T, Sato N and Yamashita T: A quest for therapeutic antigens in bone and soft tissue sarcoma. J Transl Med. 3:312005. View Article : Google Scholar : PubMed/NCBI
5	Kawano M, Nishida H, Nakamoto Y, Tsumura H and Tsuchiya H: Cryoimmunologic antitumor effects enhanced by dendritic cells in osteosarcoma. Clin Orthop Relat Res. 468:1373–1383. 2010. View Article : Google Scholar : PubMed/NCBI
6	Kanamaru F, Youngnak P, Hashiguchi M, Nishioka T, Takahashi T, Sakaguchi S, Ishikawa I and Azuma M: Costimulation via gluco-corticoid-induced TNF receptor in both conventional and CD25⁺ regulatory CD4⁺ T cells. J Immunol. 172:7306–7314. 2004. View Article : Google Scholar : PubMed/NCBI
7	McHugh RS, Whitters MJ, Piccirillo CA, Young DA, Shevach EM, Collins M and Byrne MC: CD4(+)CD25(+) immunoregulatory T cells: Gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity. 16:311–323. 2002. View Article : Google Scholar : PubMed/NCBI
8	Kohm AP, Williams JS and Miller SD: Cutting edge: Ligation of the glucocorticoid-induced TNF receptor enhances autoreactive CD4⁺ T cell activation and experimental autoimmune encephalomyelitis. J Immunol. 172:4686–4690. 2004. View Article : Google Scholar : PubMed/NCBI
9	Tone M, Tone Y, Adams E, Yates SF, Frewin MR, Cobbold SP and Waldmann H: Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells. Proc Natl Acad Sci USA. 100:15059–15064. 2003. View Article : Google Scholar : PubMed/NCBI
10	Shimizu J, Yamazaki S, Takahashi T, Ishida Y and Sakaguchi S: Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol. 3:135–142. 2002. View Article : Google Scholar : PubMed/NCBI
11	Stephens GL, McHugh RS, Whitters MJ, Young DA, Luxenberg D, Carreno BM, Collins M and Shevach EM: Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4⁺CD25⁺ T cells. J Immunol. 173:5008–5020. 2004. View Article : Google Scholar : PubMed/NCBI
12	Ko K, Yamazaki S, Nakamura K, Nishioka T, Hirota K, Yamaguchi T, Shimizu J, Nomura T, Chiba T and Sakaguchi S: Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3⁺CD25⁺CD4⁺ regulatory T cells. J Exp Med. 202:885–891. 2005. View Article : Google Scholar : PubMed/NCBI
13	Ramirez-Montagut T, Chow A, Hirschhorn-Cymerman D, Terwey TH, Kochman AA, Lu S, Miles RC, Sakaguchi S, Houghton AN and van den Brink MR: Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. J Immunol. 176:6434–6442. 2006. View Article : Google Scholar : PubMed/NCBI
14	Cohen AD, Diab A, Perales MA, Wolchok JD, Rizzuto G, Merghoub T, Huggins D, Liu C, Turk MJ, Restifo NP, et al: Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer Res. 66:4904–4912. 2006. View Article : Google Scholar : PubMed/NCBI
15	Nishikawa H, Kato T, Hirayama M, Orito Y, Sato E, Harada N, Gnjatic S, Old LJ and Shiku H: Regulatory T cell-resistant CD8⁺ T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling. Cancer Res. 68:5948–5954. 2008. View Article : Google Scholar : PubMed/NCBI
16	Turk MJ, Guevara-Patiño JA, Rizzuto GA, Engelhorn ME, Sakaguchi S and Houghton AN: Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med. 200:771–782. 2004. View Article : Google Scholar : PubMed/NCBI
17	Lutz MB and Rössner S: Factors influencing the generation of murine dendritic cells from bone marrow: The special role of fetal calf serum. Immunobiology. 212:855–862. 2007. View Article : Google Scholar : PubMed/NCBI
18	Chauvin C, Philippeau JM, Hémont C, Hubert FX, Wittrant Y, Lamoureux F, Trinité B, Heymann D, Rédini F and Josien R: Killer dendritic cells link innate and adaptive immunity against established osteosarcoma in rats. Cancer Res. 68:9433–9440. 2008. View Article : Google Scholar : PubMed/NCBI
19	Kawano M, Itonaga I, Iwasaki T, Tsuchiya H and Tsumura H: Anti-TGF-β antibody combined with dendritic cells produce antitumor effects in osteosarcoma. Clin Orthop Relat Res. 470:2288–2294. 2012. View Article : Google Scholar : PubMed/NCBI
20	Southam CM, Marcove RC, Levin AG, Buchsbaum HJ and Miké V: Proceedings: Clinical trial of autogenous tumor vaccine for treatment of osteogenic sarcoma. Proc Natl Cancer Conf. 7:91–100. 1972.PubMed/NCBI
21	Yu Z, Ma B, Zhou Y, Zhang M, Qiu X and Fan Q: Activation of antitumor cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous osteosarcoma. Exp Oncol. 27:273–278. 2005.
22	Piao J, Kamimura Y, Iwai H, Cao Y, Kikuchi K, Hashiguchi M, Masunaga T, Jiang H, Tamura K, Sakaguchi S, et al: Enhancement of T-cell-mediated anti-tumour immunity via the ectopically expressed glucocorticoid-induced tumour necrosis factor receptor-related receptor ligand (GITRL) on tumours. Immunology. 127:489–499. 2009. View Article : Google Scholar : PubMed/NCBI
23	Coe D, Begom S, Addey C, White M, Dyson J and Chai JG: Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy. Cancer Immunol Immunother. 59:1367–1377. 2010. View Article : Google Scholar : PubMed/NCBI
24	Ko HJ, Kim YJ, Kim YS, Chang WS, Ko SY, Chang SY, Sakaguchi S and Kang CY: A combination of chemoimmuno-therapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res. 67:7477–7486. 2007. View Article : Google Scholar : PubMed/NCBI
25	Nishida H, Tsuchiya H and Tomita K: Re-implantation of tumour tissue treated by cryotreatment with liquid nitrogen induces anti-tumour activity against murine osteosarcoma. J Bone Joint Surg Br. 90:1249–1255. 2008. View Article : Google Scholar : PubMed/NCBI
26	Kawano M, Itonaga I, Iwasaki T and Tsumura H: Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma. Oncol Rep. 29:1001–1006. 2013.PubMed/NCBI
27	Ronchetti S, Zollo O, Bruscoli S, Agostini M, Bianchini R, Nocentini G, Ayroldi E and Riccardi C: GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations. Eur J Immunol. 34:613–622. 2004. View Article : Google Scholar : PubMed/NCBI
28	Viguier M, Lemaître F, Verola O, Cho MS, Gorochov G, Dubertret L, Bachelez H, Kourilsky P and Ferradini L: Foxp3 expressing CD4⁺CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol. 173:1444–1453. 2004. View Article : Google Scholar : PubMed/NCBI
29	Nizar S, Meyer B, Galustian C, Kumar D and Dalgleish A: T regulatory cells, the evolution of targeted immunotherapy. Biochim Biophys Acta. 1806:7–17. 2010.PubMed/NCBI
30	Baba J, Watanabe S, Saida Y, Tanaka T, Miyabayashi T, Koshio J, Ichikawa K, Nozaki K, Koya T, Deguchi K, et al: Depletion of radio-resistant regulatory T cells enhances antitumor immunity during recovery from lymphopenia. Blood. 120:2417–2427. 2012. View Article : Google Scholar : PubMed/NCBI
31	Girardin A, McCall J, Black MA, Edwards F, Phillips V, Taylor ES, Reeve AE and Kemp RA: Inflammatory and regulatory T cells contribute to a unique immune microenvironment in tumor tissue of colorectal cancer patients. Int J Cancer. 132:1842–1850. 2013. View Article : Google Scholar
32	Suvas S, Kim B, Sarangi PP, Tone M, Waldmann H and Rouse BT: In vivo kinetics of GITR and GITR ligand expression and their functional significance in regulating viral immunopathology. J Virol. 79:11935–11942. 2005. View Article : Google Scholar : PubMed/NCBI
33	Valzasina B, Guiducci C, Dislich H, Killeen N, Weinberg AD and Colombo MP: Triggering of OX40 (CD134) on CD4(+)CD25⁺ T cells blocks their inhibitory activity: A novel regulatory role for OX40 and its comparison with GITR. Blood. 105:2845–2851. 2005. View Article : Google Scholar